CRISPR Therapeutics
CRSP
52.35
-1.65
-3.06%
CRISPR Therapeutics
US · CRSP
#2057 by market cap
Listed 2016
52.35
-1.65
-3.06%
Live - 5344 symbols - heartbeat 474s ago
· 2026-10-08 07:39
Pre-market
51.47
-1.68%
After-hours
52.65
+0.57%
Overnight
52.09
-0.50%
- Market cap
- 5.06B
- P/E (TTM)i
- -11.11
- P/Bi
- 2.90
- EPSi
- -6.47
- Div yieldi
- 0.00%
- 52W posi
- 27%
Reader sentiment
Are you bullish or bearish on CRSP?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 7.65, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -90.59% YoY
Margins
Key ratios & quality
- Altman Z-Scorei
- 7.65
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.12M | 289.59M | 719.00K | 914.96M | 1.20M | 371.21M | 37.31M | 3.51M |
| Gross profit | -- | -- | -- | 811.90M | -109.81M | 239.75M | -85.67M | -213.48M |
| Selling & admin expenses | 48.29M | 63.49M | 88.21M | 99.69M | 102.46M | 76.16M | 72.98M | 73.54M |
| Research & development | 113.77M | 179.36M | 266.95M | 340.57M | 461.65M | 387.33M | 310.24M | 381.06M |
| Operating profit | -158.94M | 46.74M | -354.44M | 373.53M | -673.16M | -222.54M | -466.57M | -664.57M |
| Pretax profit | -164.43M | 67.31M | -348.06M | 379.53M | -650.50M | -150.72M | -362.67M | -577.97M |
| Tax | 553.00K | 448.00K | 809.00K | 1.87M | -325.00K | 2.89M | 3.59M | 3.63M |
| Net profit | -164.98M | 66.86M | -348.87M | 377.66M | -650.18M | -153.61M | -366.25M | -581.60M |
| Basic EPS | -3 | 1 | -5 | 5 | -8 | -2 | -4 | -6 |
| Diluted EPS | -3.44 | 1.17 | -5.29 | 4.70 | -8.36 | -1.94 | -4.34 | -6.47 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 865.00K | 892.00K | 889.00K | 864.00K | 1.46M | 10.18M |
| Gross profit | -57.51M | -45.15M | -57.12M | -53.70M | -44.95M | -30.27M |
| Selling & admin expenses | 19.30M | 18.92M | 16.93M | 18.40M | 17.18M | 17.55M |
| Research & development | 72.48M | 166.15M | 58.90M | 83.53M | 68.57M | 69.63M |
| Operating profit | -148.42M | -229.32M | -132.06M | -154.76M | -130.25M | -117.27M |
| Pretax profit | -134.89M | -207.26M | -105.82M | -130.00M | -122.09M | -90.19M |
| Tax | 1.11M | 1.29M | 619.00K | 614.00K | 839.00K | 960.00K |
| Net profit | -136.00M | -208.55M | -106.44M | -130.61M | -122.93M | -91.15M |
| Basic EPS | -2 | -2 | -1 | -1 | -1 | -1 |
| Diluted EPS | -1.58 | -2.40 | -1.17 | -1.37 | -1.28 | -0.94 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 466.40M | 987.55M | 1.72B | 2.42B | 1.85B | 1.91B | 1.94B | 1.99B |
| Cash & ST investments | 456.65M | 943.77M | 1.69B | 2.38B | 1.82B | 1.69B | 1.90B | 1.98B |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 489.02M | 1.07B | 1.83B | 2.75B | 2.24B | 2.23B | 2.24B | 2.27B |
| Total current liabilities | 27.75M | 57.11M | 94.26M | 119.88M | 121.11M | 108.79M | 87.78M | 149.12M |
| Short-term debt | -- | 8.49M | 11.36M | 12.16M | 15.84M | 15.63M | 17.29M | 18.58M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 96,821,000.00 | 127,327,000.00 | 163,732,000.00 | 352,417,000.00 | 367,578,000.00 | 346,768,000.00 | 309,954,000.00 | 343,430,000.00 |
| Total equity | 392.20M | 939.43M | 1.66B | 2.40B | 1.88B | 1.88B | 1.93B | 1.92B |
| Retained earnings | -291.57M | -224.71M | -573.58M | -195.92M | -846.09M | -999.70M | -1.37B | -1.95B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.87B | 1.73B | 1.93B | 1.99B | 2.45B | 2.37B |
| Cash & ST investments | 1.86B | 1.72B | 1.92B | 1.98B | 2.44B | 2.36B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 2.17B | 2.03B | 2.25B | 2.27B | 2.73B | 2.65B |
| Total current liabilities | 119.45M | 104.36M | 118.96M | 149.12M | 136.29M | 132.90M |
| Short-term debt | 17.51M | 18.03M | 18.26M | 18.58M | 18.61M | 18.65M |
| Long-term debt | -- | -- | -- | -- | 585.47M | 586.20M |
| Total liabilities | 336,942,000.00 | 318,586,000.00 | 329,326,000.00 | 343,430,000.00 | 911,264,000.00 | 904,219,000.00 |
| Total equity | 1.83B | 1.71B | 1.92B | 1.92B | 1.81B | 1.75B |
| Retained earnings | -1.50B | -1.71B | -1.82B | -1.95B | -2.07B | -2.16B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -96.24M | 56.68M | -238.37M | 538.97M | -495.74M | -260.38M | -142.77M | -345.01M |
| Depreciation & amortization | 3.52M | 4.73M | 9.18M | 17.95M | 24.17M | 19.84M | 19.26M | 19.48M |
| Free cash flow | -99.01M | 49.99M | -256.72M | 457.27M | -532.93M | -272.35M | -144.68M | -370.93M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 307.00M | 415.02M | 982.29M | 213.27M | 970.00K | 32.72M | 300.70M | 398.09M |
| Ending cash balance | 459.81M | 948.81M | 1.19B | 939.94M | 224.06M | 401.07M | 309.78M | 359.08M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -53.95M | -113.88M | -84.63M | -92.55M | -108.90M | -83.50M |
| Depreciation & amortization | 4.74M | 4.65M | 4.43M | 5.66M | 4.32M | 4.28M |
| Free cash flow | -54.15M | -139.00M | -84.71M | -93.07M | -109.40M | -86.62M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 8.52M | -22.00K | 278.11M | 111.49M | -- | -- |
| Ending cash balance | 246.70M | 205.14M | 298.02M | 359.08M | 431.31M | 299.34M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -56.89 | 10.04 | -26.80 | 18.59 | -30.42 | -8.17 | -19.20 | -30.18 |
| ROA %i | -43.40 | 8.59 | -24.10 | 16.49 | -26.03 | -6.87 | -16.38 | -25.81 |
| ROIC %i | -56.89 | 9.31 | -25.67 | 17.36 | -27.41 | -7.24 | -17.13 | -27.15 |
| 5-year avg ROE %i | -- | -- | -25.78 | -17.51 | -17.09 | -7.35 | -13.20 | -13.88 |
| EBIT margin %i | -5,263.38 | 16.14 | -65,273.48 | 40.91 | -154,394.72 | -60.15 | -1,333.05 | -- |
| FCF / sales %i | -- | 17.26 | -- | 50.08 | -- | -- | -- | -- |
| Current ratioi | 16.81 | 17.29 | 18.21 | 20.17 | 15.30 | 17.54 | 22.07 | 13.32 |
| Quick ratioi | 16.46 | 16.53 | 17.93 | 19.85 | 14.99 | 17.41 | 21.97 | 13.25 |
| Debt / assetsi | 0.00 | 4.93 | 3.36 | 8.18 | 10.88 | 10.70 | 9.98 | 9.13 |
| LT debt / equityi | -- | 4.69 | 3.01 | 8.87 | 12.17 | 11.84 | 10.68 | 9.79 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 132.99 | 282.77 | -76.34 | 563.64 | -88.54 | 779.97 | -66.28 | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -19.71 | -25.34 | -25.33 | -30.18 | -31.21 | -26.09 |
| ROA %i | -16.75 | -21.41 | -21.70 | -25.81 | -23.24 | -19.28 |
| ROIC %i | -17.66 | -22.61 | -22.74 | -27.15 | -24.45 | -20.24 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -1,355.44 | -1,578.47 | -1,641.13 | -- | -64,639.50 | -4,857.64 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 15.64 | 16.61 | 16.22 | 13.32 | 17.96 | 17.85 |
| Quick ratioi | 15.53 | 16.49 | 16.10 | 13.25 | 17.92 | 17.79 |
| Debt / assetsi | 10.13 | 10.61 | 9.40 | 9.13 | 28.90 | 29.57 |
| LT debt / equityi | 11.04 | 11.54 | 10.06 | 9.79 | 42.38 | 43.81 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Discovering, developing and commercializing therapies.100.00%
Quote time 2026-10-08 07:39:07 · For reference only, not investment advice and not tailored to your situation.